Privium Fund Management’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History

Privium Fund Management’s Portfolio BCTXW Stock Details BCTXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-64,907	Closed	-$159K	–	116
2023 Q2	$159K	Sell	64,907 -57,177	-47%	-$158K	0.05%	76
2023 Q1	$361K	Sell	122,084 -196,876	-62%	-$566K	0.12%	53
2022 Q4	$622K	Buy	318,960 +45,306	+17%	+$106K	0.24%	43
2022 Q3	$710K	Buy	273,654 +78,837	+40%	+$236K	0.26%	52
2022 Q2	$507K	Buy	+194,817	New	+$622K	0.17%	68

Other funds holding BCTXW

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Privium Fund Management's BCTXW Position: Q3 2023 in Review

Privium Fund Management sold out of BriaCell Therapeutics Corp Warrant (BCTXW) in Q3 2023, closing a stake of 64,907 shares — an estimated $159K sold.

Privium Fund Management first reported a position in BCTXW in Q2 2022 and held it in 5 quarters. The position peaked at $710K in Q3 2022. 4 funds tracked by Wall St. Rank hold BCTXW as of Q3 2023.

Privium Fund Management reported no remaining BriaCell Therapeutics Corp Warrant position as of Q3 2023 after selling out during the quarter.
Privium Fund Management sold 64,907 BriaCell Therapeutics Corp Warrant shares in Q3 2023, an estimated $159K.
Privium Fund Management first reported a position in BriaCell Therapeutics Corp Warrant in Q2 2022 and held it in 5 quarters.
Privium Fund Management's BriaCell Therapeutics Corp Warrant position peaked at $710K in Q3 2022.
4 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q3 2023.

Based on Privium Fund Management's 13F filing for Q3 2023, filed 6 Nov 2023.